Literature DB >> 18202308

Neuroprotection: still achievable in humans.

Geoffrey A Donnan1, Stephen M Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18202308     DOI： 10.1161/STROKEAHA.107.494807

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  7 in total

Review 1.  Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke.

Authors:  Yao-Hui Tang; Yuan-Yuan Ma; Zhi-Jun Zhang; Yong-Ting Wang; Guo-Yuan Yang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

2.  Combined Gene Therapy to Reduce the Neuronal Damage in the Mouse Model of Focal Ischemic Injury.

Authors:  Lior Molcho; Tali Ben-Zur; Yael Barhum; Ariel Angel; Mica Glat; Daniel Offen
Journal:  J Mol Neurosci       Date:  2018-09-03       Impact factor: 3.444

3.  The Continued Promise of Neuroprotection for Acute Stroke Treatment.

Authors:  Shimin Liu; Steven R Levine
Journal:  J Exp Stroke Transl Med       Date:  2008

Review 4.  Role of cannabinoids and endocannabinoids in cerebral ischemia.

Authors:  Cecilia J Hillard
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 5.  Lipoxygenase: an emerging target for stroke therapy.

Authors:  Klaus van Leyen
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-03       Impact factor: 4.388

Review 6.  Neuroprotection in acute ischemic stroke--current status.

Authors:  E Auriel; N M Bornstein
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

7.  Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers.

Authors:  Pandora Pound; Rebecca Ram
Journal:  BMJ Open Sci       Date:  2020-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.